New stock news | Yusys Technologies (300674.SZ) submits a second application to the Hong Kong Stock Exchange
According to the disclosure by the Hong Kong Stock Exchange on December 24th, Beijing Yuxin Technology Group Co., Ltd. (referred to as Yuxin Technology, 300674.SZ) has submitted an application for listing on the main board of the Hong Kong Stock Exchange, with Huatai International and BNP Paribas serving as its joint sponsors.
According to the disclosure by the Hong Kong Stock Exchange on December 24th, Beijing Yusys Technologies Group Co., Ltd. (referred to as Yusys Technologies, 300674.SZ) has submitted an application to list on the main board of the Hong Kong Stock Exchange, with Huatai International and BNP Paribas as its joint sponsors. This is the company's second filing this year, as it had previously submitted a listing application to the Hong Kong Stock Exchange on June 18th. The prospectus shows that Yusys Technologies is a listed Chinese financial technology solutions provider with operations in both domestic and overseas markets, offering product-oriented full-stack technology solutions to a wide range of financial institutions. During the reporting period, the company's main business consisted of three major segments: banking technology solutions, non-banking technology solutions, and operational services. The company's banking and non-banking technology solutions include credit business, digital banking business, financial regulatory business, data business, and intelligent financial business. In addition, the company is developing operational services with a focus on ecological cooperation and partnership relationships.
Related Articles

Blood disease drug approved by the FDA for expanded use, Agios Pharmaceuticals (AGIO.US) stock price soared nearly 20%.

A-share pre-market report: The United States will stop imposing additional tariffs on Chinese chips in the next 18 months. Beijing has introduced a series of measures for the real estate market.

Securities Morning Meeting Highlights | Technological Breakthroughs and Capital Empowerment to Accelerate the Industrialization of Nuclear Fusion. Focus on Midstream and Upstream Investment Opportunities.
Blood disease drug approved by the FDA for expanded use, Agios Pharmaceuticals (AGIO.US) stock price soared nearly 20%.

A-share pre-market report: The United States will stop imposing additional tariffs on Chinese chips in the next 18 months. Beijing has introduced a series of measures for the real estate market.

Securities Morning Meeting Highlights | Technological Breakthroughs and Capital Empowerment to Accelerate the Industrialization of Nuclear Fusion. Focus on Midstream and Upstream Investment Opportunities.

RECOMMEND





